BRAF and neoplasm: Additionally, because both KRAS c.34G>T (p.G12C) mutation and BRAF mutation were associated with CIMP‐high status, we conducted exploratory analyses comparing clinical and tumor characteristics between KRAS c.34G>T (p.G12C)‐mutated and BRAF‐mutated tumors (Table S1).